A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma

Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, Von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE (2014)

Publication Type: Journal article

Publication year: 2014

Journal

Clinical Cancer Research American Association for Cancer Research

Book Volume: 20

Pages Range: 6304-6313

Journal Issue: 24

DOI: 10.1158/1078-0432.CCR-14-0951-T

Abstract

Purpose: Preclinical data indicate anti-invasive activity of APG101, a CD95 ligand (CD95L)-binding fusion protein, in glioblastoma.

Authors with CRIS profile

Christian Hartmann Lehrstuhl für Technische Elektronik

Involved external institutions

Universitätsklinikum Heidelberg DE Germany (DE) Apogenix GmbH DE Germany (DE) Nikolay Nilovich Burdenko Neurosurgery Institute / Центр нейрохирургии имени академика Н. Н. Бурденко RU Russian Federation (RU) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) DE Germany (DE) Kepler Universitätsklinikum (KUK) AT Austria (AT)

How to cite

APA:

Wick, W., Fricke, H., Junge, K., Kobyakov, G., Martens, T., Heese, O.,... Combs, S.E. (2014). A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clinical Cancer Research, 20(24), 6304-6313. https://doi.org/10.1158/1078-0432.CCR-14-0951-T

MLA:

Wick, Wolfgang, et al. "A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma." Clinical Cancer Research 20.24 (2014): 6304-6313.

BibTeX: Download